Covid Antibody Testing Study in Cancer Patients

Clinical Trial Title

Evaluation of cancer patients for evidence of SARSCoV- 2 IgG seroconversion.

Clinical Trial Protocol Description:

With this study, we are trying to better understand COVID-19 infection in cancer patients by test their blood for IgG antibodies to Covid-19.We also plan to investigate how long these antibodies would last and whether they are protective against future infection to COVID-19.This study will also help in identifying those cancer patients who may be at increased risk of infection with COVID-19 and will help in better risk categorization and preventive measures against the COVID-19 infection.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have a history of malignancy at the RUCC and have either not started treatment, are on active treatment or have completed treatment.
  • Are at least 18 years of age.
  • Are willing to provide informed consent.

You will be excluded from the study if any of the following criteria apply to you:

  • Are unwilling to provide informed consent.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Ankur Varma, MD

Contact Information

Praneeth Chebrolu MBBS, MS